2 days Ago By ABMN Staff
Geode Capital Management LLC raised its position in shares of Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX – Free Report ) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.
The firm owned 3,813,207 shares of the company’s stock after buying an additional 26,536 shares during the quarter. Geode Capital Management LLC’s holdings in Amneal Pharmaceuticals were worth $30,207,000 at the end of the most recent quarter. A number of other hedge funds have also recently modified their holdings of the business.
Mirae Asset Global Investments Co. Ltd. purchased a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $81,000.
Cibc World Markets Corp purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $118,000. Janney Montgomery Scott LLC bought a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $121,000. Fox Run Management L.
L.C. grew its stake in shares of Amneal Pharmaceuticals by 69.
0% in the 4th quarter. Fox Run Management L.L.
C. now owns 20,435 shares of the company’s stock worth $162,000 after buying an additional 8,342 shares during the last quarter. Finally, KLP Kapitalforvaltning AS bought a new position in Amneal Pharmaceuticals during the 4th quarter valued at approximately $219,000.
Institutional investors own 31.82% of the company’s stock. Insiders Place Their Bets In other Amneal Pharmaceuticals news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the business’s stock in a transaction dated Friday, March 14th.
The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00.
Following the completion of the sale, the insider now directly owns 48,578,209 shares in the company, valued at $405,628,045.15. The trade was a 9.
33 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink . Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction that occurred on Monday, March 3rd.
The stock was sold at an average price of $8.90, for a total transaction of $712,000.00.
Following the completion of the transaction, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. This trade represents a 4.
24 % decrease in their position. The disclosure for this sale can be found here . In the last quarter, insiders sold 5,160,000 shares of company stock valued at $43,113,200.
Company insiders own 26.56% of the company’s stock. Amneal Pharmaceuticals Price Performance Amneal Pharmaceuticals ( NASDAQ:AMRX – Get Free Report ) last announced its quarterly earnings results on Friday, February 28th.
The company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.
03). Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.
26%. The company had revenue of $730.52 million for the quarter, compared to analysts’ expectations of $708.
21 million. During the same period in the previous year, the business earned $0.14 EPS.
As a group, sell-side analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth A number of research firms have recently commented on AMRX. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $9.
00 to $12.00 in a research note on Monday, February 24th. Barclays increased their price objective on shares of Amneal Pharmaceuticals from $10.
00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, March 3rd. Finally, StockNews.
com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $10.
80. View Our Latest Stock Report on AMRX Amneal Pharmaceuticals Company Profile ( Free Report ) Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE.
The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. Read More Want to see what other hedge funds are holding AMRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amneal Pharmaceuticals, Inc.
( NASDAQ:AMRX – Free Report ). Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
_0.jpg?itok=yAIF6nFK)
